Key result
Patient-specific human-induced pluripotent stem cells provide a novel in-vitro model to study the molecular mechanisms of familial cardiomyopathies and facilitate drug screening and discovery.
Patient-specific iPSCs provide a novel in-vitro model for studying the molecular mechanisms of inherited cardiomyopathies and for drug screening.
iPSC models may aid mechanistic studies and drug screening in familial cardiomyopathies; leaves open clinical translation pending validation.
PURPOSE OF REVIEW: This article provides an overview of the latest advances in in-vitro modeling of inherited cardiomyopathies using human-induced pluripotent stem cells (iPSCs). RECENT FINDINGS: Inherited cardiomyopathies have been recently modeled by generating iPSCs from patients harboring mutations in genes associated with the pathogenesis of hypertrophic cardiomyopathy, dilated cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy/dysplasia. SUMMARY: Patient-specific iPSCs and their differentiated cardiomyocytes (induced pluripotent stem cell-derived cardiomyocytes) now provide a novel model to study the underlying molecular mechanism of the pathogenesis of familial cardiomyopathies as well as for in-vitro drug screening and drug discovery.
No takes yet. Share an insight, caveat, or question.
Karakikes et al. (2014) conducted a review in Inherited cardiomyopathies. Human-induced pluripotent stem cells (iPSCs) modeling was evaluated. Patient-specific human-induced pluripotent stem cells provide a novel in-vitro model to study the molecular mechanisms of familial cardiomyopathies and facilitate drug screening and discovery.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: